SAN FRANCISCO – Mylan CEO Heather Bresch reflected Wednesday on what she learned from months of public outrage over her company’s dramatic price increase for the EpiPen allergy shot.
“I think the most valuable lesson learned is that the pricing model has got to change,” Bresch said at the JPMorgan Healthcare Investor Conference. “It’s not incremental change. I think it’s truly rethinking the business model.”
Asked what a new pricing model might look like, Bresch said she doesn’t have all the answers but is spending time with her team thinking about it.
“I know that scares everyone,” Bresch told attendees. But avoiding the issue is out of the question, she added.
“I think if anyone is walking away from this conference thinking business as usual, I think that’s a mistake,” Bresch said.
Bresch testified before Congress in the fall, when lawmakers demanded an explanation for why Mylan raised the price of the widely used EpiPen by 400 percent. Mylan is one of several pharmaceutical companies widely criticized in recent years for raising the price of existing drugs.
Bresch is the daughter of West Virginia Sen. Joe Manchin, a Democrat.
